Seong completed a PhD degree in Cytogenetics lab at Biomedical Laboratory of Science at Yonsei University, Korea, in 2018. While there, he primarily focused on development of anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis. He worked on developing several type of lipid-based drug delivery systems that can deliver nucleic acid therapeutics or chemical drug to tumor.
In his first postdoctoral position at Korea Institute of Science and Technology (KIST), he worked on developing nucleic acid-based drug delivery system against tumor and pulmonary fibrosis. He also investigated a strategy that can improve the activity of CRISPR/Cas system using chimeric crRNA.
In the Lesniak lab, he will focus on developing improved therapeutic strategies using nanotherapeutics for brain tumor treatment.